JPWO2021202770A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021202770A5 JPWO2021202770A5 JP2022559585A JP2022559585A JPWO2021202770A5 JP WO2021202770 A5 JPWO2021202770 A5 JP WO2021202770A5 JP 2022559585 A JP2022559585 A JP 2022559585A JP 2022559585 A JP2022559585 A JP 2022559585A JP WO2021202770 A5 JPWO2021202770 A5 JP WO2021202770A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cell
- targeting agent
- subject
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003203P | 2020-03-31 | 2020-03-31 | |
| US63/003,203 | 2020-03-31 | ||
| PCT/US2021/025220 WO2021202770A2 (en) | 2020-03-31 | 2021-03-31 | Human anti-cd33 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023520399A JP2023520399A (ja) | 2023-05-17 |
| JPWO2021202770A5 true JPWO2021202770A5 (https=) | 2024-03-28 |
| JP2023520399A5 JP2023520399A5 (https=) | 2024-03-28 |
Family
ID=77929454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559585A Pending JP2023520399A (ja) | 2020-03-31 | 2021-03-31 | ヒト抗ｃｄ３３抗体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230144405A1 (https=) |
| EP (1) | EP4126248A4 (https=) |
| JP (1) | JP2023520399A (https=) |
| CN (1) | CN115397515A (https=) |
| CA (1) | CA3173205A1 (https=) |
| WO (1) | WO2021202770A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| WO2021202799A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Chimeric antigen receptors targeting cd33 |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| JP2024539650A (ja) * | 2021-10-15 | 2024-10-29 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能なポリペプチド複合体 |
| US20240173425A1 (en) * | 2022-06-22 | 2024-05-30 | Eli Lilly And Company | Human cd33 antibodies and glucocorticoid conjugates |
| CN121591894A (zh) * | 2024-08-23 | 2026-03-03 | 南京北恒生物科技有限公司 | 靶向cd33的抗体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010072740A2 (en) * | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| CN103145849B (zh) * | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
| US20190233534A1 (en) * | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| SG11201907870VA (en) * | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| GB201707779D0 (en) * | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
| US12116406B2 (en) * | 2017-05-26 | 2024-10-15 | Fred Hutchinson Cancer Center | Anti-CD33 antibodies and uses thereof |
| US12227763B2 (en) * | 2018-05-11 | 2025-02-18 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
-
2021
- 2021-03-31 CA CA3173205A patent/CA3173205A1/en active Pending
- 2021-03-31 CN CN202180025735.8A patent/CN115397515A/zh active Pending
- 2021-03-31 JP JP2022559585A patent/JP2023520399A/ja active Pending
- 2021-03-31 US US17/907,655 patent/US20230144405A1/en active Pending
- 2021-03-31 WO PCT/US2021/025220 patent/WO2021202770A2/en not_active Ceased
- 2021-03-31 EP EP21781573.7A patent/EP4126248A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hosseini et al. | Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials | |
| JP2025016606A5 (https=) | ||
| JP2024150751A5 (https=) | ||
| JP2023123726A5 (https=) | ||
| JP2025060941A5 (https=) | ||
| JP2021524244A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2023106433A5 (https=) | ||
| JP2016505556A5 (https=) | ||
| JP2018519263A5 (https=) | ||
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| CA2284829A1 (en) | Immunotherapy of b-cell malignancies using anti-cd22 antibodies | |
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| JP2018534933A5 (https=) | ||
| JPWO2019224711A5 (https=) | ||
| JP2012510282A5 (https=) | ||
| JPWO2019246514A5 (https=) | ||
| JP2025183307A5 (https=) | ||
| JP2016503067A5 (https=) | ||
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP2020515577A5 (https=) | ||
| JP2021504414A5 (https=) | ||
| JP2021525806A5 (https=) | ||
| JPWO2021202770A5 (https=) | ||
| JPWO2021168303A5 (https=) |